TY - CHAP M1 - Book, Section TI - Immunotherapy: Past, Present and Future A1 - Hill, Samuel L. A1 - Johnson, Peter W.M. A2 - Board, Ruth E. A2 - Nathan, Paul A2 - Newsom-Davis, Tom A2 - Papa, Sophie A2 - Johnson, Peter Y1 - 2019 N1 - T2 - Problem Solving in Cancer Immunotherapy AB - The intuitive appeal of eliciting an effective immune response against cancers has long been recognized but, until quite recently, rarely fulfilled. At the end of the 19th century, William Coley, a New York sarcoma surgeon, noted some tumour regressions in cancer patients infected with streptococci, by provoking an immune response.1 But such responses proved hard to replicate and his treatments quickly fell out of favour. The idea, however, remained potent. Occasional instances of spontaneous tumour regression2,3 or prolonged dormancy suggested some form of ‘host restraint’, and a number of clinical successes kept the field of immunotherapy alive, despite the many failed attempts at treatment. SN - PB - EBN Health CY - New York, NY Y2 - 2021/01/27 UR - hemonc.mhmedical.com/content.aspx?aid=1160632587 ER -